The effectiveness of instrument-assisted soft tissue mobilization on pain and function in patients with musculoskeletal disorders: a systematic review and meta-analysis.

Researchers pooled data from eleven randomized controlled trials involving 427 people to examine whether instrument-assisted soft tissue mobilization (IASTM) helps with musculoskeletal pain and function. IASTM involves using handheld tools to treat muscle and connective tissue, and while it is widely used in clinical practice, the research supporting it has been mixed. The analysis found moderate-certainty evidence that IASTM reduces pain when combined with other treatments, and lower-certainty evidence that it improves function.

However, the quality of the underlying studies was mixed, with six out of eleven having a high risk of bias. The effect sizes were small to modest, and the authors concluded that future research does not need to replicate short-term pain studies in neck pain and headache, suggesting the evidence in those specific conditions has reached a sufficient threshold.

A team of researchers looked at whether a hands-on treatment called IASTM, which uses special tools to work on tight muscles and tissues, actually helps people with long-lasting musculoskeletal pain. They combined results from eleven studies and found that people who received IASTM alongside other treatments did report somewhat less pain compared to those who received other treatments alone.

They also found signs that function and movement improved a little, though this finding was less certain than the pain reduction. The improvements were real but modest, not dramatic turnarounds. The researchers were fairly confident about the pain findings but less confident about function, mainly because fewer studies looked at that outcome and the quality of some studies was not as strong as it could have been.

This means IASTM may be part of a helpful treatment package, but it is not a standalone solution, and more research is still needed to understand exactly how much it helps and who benefits most.

This is a summary of research, not medical advice. Talk to your own healthcare provider about anything affecting your care.

This meta-analysis of eleven RCTs offers moderate-certainty evidence that IASTM combined with other interventions produces a small but measurable reduction in patient-reported pain (standardized mean difference of 0.60), with a fairly tight confidence interval. The evidence for functional improvement is considerably weaker, both in certainty rating and in the magnitude of effect (SMD 0.40), and only eight trials contributed to that analysis.

A notable limitation is that six of the eleven included trials carried high risk of bias, and the authors did not perform meta-analysis on pain pressure threshold due to insufficient data. The trial sequential analysis found that the cumulative evidence crossed the threshold for superiority in the specific subset of nonspecific chronic neck pain and cervicogenic headache at the four-week mark, which the authors view as sufficient to conclude future short-term efficacy studies in those conditions are unnecessary. That finding is worth noting as a potential boundary of the evidence base.

Overall, the effect sizes are consistent with a modest adjunctive benefit rather than a strong primary effect, and heterogeneity in study design and patient populations remains a consideration for clinical translation.